Caplin Point Laboratories Ltd (CAPLIPOINT) is currently trading at 2,336.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Caplin Point Laboratories is an integrated pharmaceutical company focused on finished dosage generics and specialty injectables, predominantly serving emerging markets in Latin America and Africa while expanding into regulated markets such as the US through subsidiaries like Caplin Steriles and Caplin Steriles USA. Q1 FY27 consolidated revenue was ₹644 crore (up 20.7% YoY) and PAT ₹179 crore (up 18.8% YoY), supported by robust gross margins near 60% and EBITDA margin of 38.4%, reflecting profitable growth driven by a mix of emerging-market sales and accelerating US contribution. Management has allocated an enhanced capex envelope of ~₹1,000+ crore to expand OSD, dermatology, injectables, oncology API and CSL capacity, with roughly half the spend nearing completion and the remainder to be incurred over the next 2–3 years, fully funded from internal accruals. Caplin Point reports substantial liquidity — free cash reserves of ₹1,502 crore and total liquid assets of ₹2,875 crore — enabling debt-free capex funding and supporting strategic launches, backward integration via API DMF filings, and multiple tender wins in Latin America. The company’s regulated-market push is tangible: 60 ANDAs approved (50 internally developed), 38 US launches to date, CSL pipeline of PFS and injectable filings, and a plan to file 60+ products across non-US regulated markets over the next 18 months for Caplin Point’s growth engine.

Over the past 52 weeks, Caplin Point Laboratories Ltd has traded between a low of ₹1,502.45 and a high of ₹2,990.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Caplin Point Laboratories Ltd has a market capitalization of approximately 18,042.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Caplin Point Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.12 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 18,042.14 Cr, Caplin Point Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Caplin Point Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd is 27.12. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Caplin Point Laboratories has set September 18, 2026 as the record date for eligibility for the 35th AGM and the FY2025-26 final dividend, if declared.

Caplin Point reported consolidated net profit of ₹179.09 crore for Q1 FY27, up 18.8% from ₹150.76 crore in Q1 FY26.

For the quarter ended December 2025, consolidated sales rose 10.10% to ₹542.77 crore and net profit rose 17.93% to ₹163.88 crore.

Caplin Steriles received final USFDA approval for its ANDA for Calcium Gluconate Injection USP (100 mg/mL) in 10 mL, 50 mL and 100 mL vials.